bulumtatug fuvedotin

Phase 1Small molecule

MMabwell (Shanghai) Bioscience Co., Ltd.

bulumtatug fuvedotin is one of 8 small molecule programs targeting TNBC. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TNBCRecruiting

TNBCPhase 1

Recruiting

Competition

Competitive Landscape

7 competitors in TNBC

#DrugCompanyPhaseTrials

Kisqali

Novartis

Phase 2

1 2

Casodex

IIstituto Clinico Humanitas

Phase 2

2 3

Navmi

SSummit Therapeutics

Phase 2

1 4

Paraplatin

AAvyxa

Phase 2

1 5

Taxotere

AAvyxa

Phase 2

1 6

Jakafi

Incyte

Phase 1

1 7

Nerlynx

PPuma Biotechnology, Inc.

Phase 1

1 8

bulumtatug fuvedotin

MMabwell (Shanghai) Bioscience Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

TNBC

NCT06908928

Clinical

Trials by Indication[1]

TNBC1 trial

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

Recruiting·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 1·NCT06908928·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for bulumtatug fuvedotin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — bulumtatug fuvedotin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for bulumtatug fuvedotin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mabwell (Shanghai) Bioscience Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMabwell (Shanghai) Bioscience Co., Ltd.

bulumtatug fuvedotin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

TNBC1 trial

References

Drug Info

Quick Facts

Related News